Pipeline

Over 60% of new drugs are poorly water soluble. Traditional drug solubilizers (solvents & surfactants) are toxic and cause side effects. The problem occurs when cancers become drug resistant to current cancer therapies. Our LASSN™ platform approach is safer, faster, and more efficacious enabling us to accelerate the development and commercialization of life saving therapies.

IND enabling study for Immediate release Taxane based nanomedicine with first of its kind drug resistant sensitizer.

First-in-class immediate release nanomedicine microtubule inhibitor effective against Taxane resistant & p-glycoprotein drug resistant cancers.

Advanced first in class immediate release second generation Taxane based chemotherapy. Incorporate drug resistance & targeting sensitizers. Pre-clinical formulation and batches complete, MTD animal testing in progress, optimizing dosing schedules. New immediate release patent filed in April 2019.

Active CMC development in process

First-in-class 3rd generation Taxane that crosses the blood brain barrier (BBB) to treat Brain Cancer. API synthesis in process using our nanotechnology to create multiple analogues and rational drug combinations.

New chemical entity (NCE) kinase inhibitor analogue molecules have been designed.

Oncology

Candidates	Indications	Regulatory Pathway	Development	Preclinical	Phase 1	Phase 2	Phase 3
LBI-0609	Neuroendocrine, Lung, Pancreas, TNBC (Breast) Cancer	505(b)(2) with improved formulation		IND enabling study
		Immediate release Taxane based nanomedicine with first of its kind drug resistant sensitizer.
LBI-0996	Taxane resistant metastatic & Advanced Breast Cancer	505(b)(2) with improved formulation
		First-in-class immediate release nanomedicine microtubule inhibitor effective against Taxane resistant & p-glycoprotein drug resistant cancers.
LBI-1103	Prostate, Breast, Lung, Head & Neck, Ovarian, Stomach Cancer	New NDA
		Advanced first in class immediate release second generation Taxane based chemotherapy. Incorporate drug resistance & targeting sensitizers. Pre-clinical formulation and batches complete, MTD animal testing in progress, optimizing dosing schedules. New immediate release patent filed in April 2019.
LBI-0942	Breast, Lung, Pancreas Cancer	Generic ANDA
		Active CMC development in process
LBI-1123	Glioblastoma & Metastatic	New NDA
		First-in-class 3rd generation Taxane that crosses the blood brain barrier (BBB) to treat Brain Cancer. API synthesis in process using our nanotechnology to create multiple analogues and rational drug combinations.
LBI-0222	Multiple Myeloma, Leukemia	New NDA
		New chemical entity (NCE) kinase inhibitor analogue

First non-toxic dosage forms of CBD & THC: IV, Inhalation, Oral & Ophthalmic. Pre-clinical 55 nanometer CBD based formulation complete. New LASSN Cannabis patents filed March 2019.

Pain Therapy

Candidates	Indications	Regulatory Pathway	Development	Preclinical	Phase 1	Phase 2	Phase 3
LBI-1026	Pain, Nausea & Vomiting, Epilepsy, Neuropathy, Glaucoma	Improved 505(b)(2) Formulations
		First non-toxic dosage forms of CBD & THC: IV, Inhalation, Oral & Ophthalmic. Pre-clinical 55 nanometer CBD based formulation complete. New LASSN Cannabis patents filed March 2019.